Market Place
Sourcing Support
Emmaus Life Sciences Reports Quarterly Financial Results
10 Sep 2024 //
PR NEWSWIRE
Emmaus Life Sciences Appoints Willis C. Lee as CEO
23 Jul 2024 //
CONTRACT PHARMA
Emmaus Life Sciences Reports 2023 Financial Results
03 Jul 2024 //
PR NEWSWIRE
Emmaus Life Sciences Reports Q3 2023 Financial Results
14 Nov 2023 //
PR NEWSWIRE
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman
13 Jul 2023 //
PR NEWSWIRE
Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update
31 Mar 2023 //
PR NEWSWIRE
Endari Receives Kuwaiti Marketing Authorization
07 Dec 2022 //
PRNEWSWIRE
Emmaus Receives Endari Marketing Authorization from the Qatar Ministry
17 Nov 2022 //
PRNEWSWIRE
Emmaus Announces Collaboration with Kier (Junior) Spates
28 Sep 2022 //
PRNEWSWIRE
Emmaus Life Sciences Reports Q2 2022 Financial Results, Provides Business Update
15 Aug 2022 //
PRNEWSWIRE
Emmaus Life Sciences Announces Engagement of Strategic Business Relations
12 Jul 2022 //
PRNEWSWIRE
Emmaus Life Sciences Reports Q1 2022 Financial Results
13 May 2022 //
PRNEWSWIRE
Emmaus Life Sciences to Present at Investor Conferences in May
26 Apr 2022 //
PRNEWSWIRE
Emmaus Life Sciences Presented Positive Real-World Data on Efficacy of Endari
07 Apr 2022 //
PRNEWSWIRE
Emmaus Says Endari To Be Added to Florida Medicaid Preferred Drug List
29 Mar 2022 //
PRNEWSWIRE
Emmaus Life Sciences` Real World Data on Endari Accepted for E-Poster
04 Mar 2022 //
PRNEWSWIRE
Emmaus Life Sciences Reports 3Q Financial Results and Business Highlights
13 Nov 2021 //
PRNEWSWIRE
Emmaus Life Sciences Partners with UpScript to Provide Telehealth Solutions
11 Nov 2021 //
PRNEWSWIRE
Emmaus Life Sciences Enters into Agreement with Asembia
04 Nov 2021 //
PRNEWSWIRE
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4
12 Oct 2021 //
PRNEWSWIRE
Emmaus Life Sciences Announces Bahrain Temporary License of Endari®
17 Aug 2021 //
PRNEWSWIRE
Emmaus Life Sciences Submits Endari® Marketing Authorization Application
15 Jul 2021 //
PR NEWSWIRE
Emmaus Submits Marketing Authorization Application to Swissmedic Ideogen
15 Jun 2021 //
PRNEWSWIRE
Emmaus Life Announces Submission of Marketing Authorization for Endari®
27 May 2021 //
PRNEWSWIRE
Emmaus Life Sciences Announces Submission of MarketAuthorization for Endari®
26 May 2021 //
PRNEWSWIRE
Emmaus Life Sciences Reports Annual Financial Results for 2020
04 May 2021 //
PRNEWSWIRE
Emmaus Life Sciences Announces Collaboration with Kainos Medicine
02 Mar 2021 //
PRNEWSWIRE
Emmaus Life Announces Collaboration with Kainos Medicine for Preclinical DeveP
02 Mar 2021 //
PRNEWSWIRE
Emmaus Life Sciences Reports Annual Financial Results for 2019
25 Jan 2021 //
BUSINESSWIRE
Emmaus Life Sciences Launches Endari® Support Program
08 Dec 2020 //
PRNEWSWIRE
Emmaus Life Sciences Submits Temporary License App in Bahrain for Endari®
10 Nov 2020 //
PRNEWSWIRE
Emmaus Life Sciences Announces Submission of Marketing Authorization ApplicatioN
18 Aug 2020 //
GLOBENEWSWIRE
Emmaus Life Sciences Reports Additional +VE Preliminary Results Diverticulosis
05 Aug 2020 //
GLOBENEWSWIRE
Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates
31 Jul 2020 //
GLOBENEWSWIRE
Emmaus Life Sciences Accelerates Middle East and North Africa (MENA)
23 Jul 2020 //
GLOBENEWSWIRE
Emmaus Life Sciences Announces Engagement of Partner International
16 Jul 2020 //
BIOSPACE
Emmaus Life Announces Engagement of Partner Lead Out-Licensing of Endari®
16 Jul 2020 //
GLOBENEWSWIRE
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli
29 Jun 2020 //
GLOBENEWSWIRE
Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare
23 Dec 2019 //
GLOBE NEWSWIRE
Emmaus Receives Notice of Allowance for Japanese Patent for use of L-glutamine
07 Feb 2017 //
PR NEWSWIRE
Emmaus Receives Japanese Patent for use of L-glutamine
13 Dec 2016 //
PR NEWSWIRE
Emmaus` New Drug Application for Sickle Cell Disease Accepted for Review by FDA
08 Nov 2016 //
PR NEWSWIRE
Emmaus Medical Signs Agreement with Tokyo-Based Regenerative Medicine Company
17 Jun 2016 //
PR NEWSWIRE
